ASNC has confirmed reports that supply disruptions with both Tc-99m pyrophosphate (PYP) and Tc-99m hydroxymethylene diphosphonate (HMDP or HDP) may take place after January 2026. These products are used in the diagnosis of cardiac amyloidosis.
ASNC is in contact with the manufacturers of both products to understand the extent of the shortages and the projected timelines for resuming production.
ASNC will share updates as this issue evolves. To be among the first to receive email alerts with breaking news, be sure to keep your ASNC membership current.
Article Type
News & Announcements
Category
Advocacy
Related Posts
PYP Production Resumes at Sun Radiopharma; Curium Continues Regular Production
Your ASNC team stays in close touch with radiopharmaceutical manufacturers and radiopharmacies…
ASNC Industry Forum Brings Leaders Together to Brainstorm Advancing Nuclear Cardiology
Strengthening nuclear cardiology’s position in the increasingly competitive cardiovascular imaging landscape was…
ASNC’s First AI Summit Explores Opportunities to Advance Nuclear Cardiology
“The ASNC AI Summit brought together a tremendous range of expertise and…


